10-K: Coeptis Therapeutics Holdings Reports Full Year 2023 Results, Cites Ongoing Development and Strategic Partnerships

Coeptis Therapeutics Holdings, Inc. released its 2023 annual report, highlighting continued development of its product pipeline and strategic partnerships, while also noting significant operating losses.

Summary

• Coeptis Therapeutics Holdings, Inc. reported a net loss of $21.27 million for the year ended December 31, 2023, and an accumulated deficit of $87.36 million.
• The company's operating expenses decreased to $21.48 million in 2023 from $34.20 million in 2022, primarily due to reduced strategic financing costs.
• Coeptis is focused on developing its product pipeline, including CD38-GEAR-NK, CD38-Diagnostic, and SNAP-CAR technologies, and is exploring strategic partnerships.
• The company completed an exclusive licensing agreement with Deverra Therapeutics, acquiring key patents and assets related to stem cell expansion and NK cell therapies.
• Coeptis raised $2 million in gross proceeds through a private placement in October 2023, and $3 million through private sales in September 2023.
• The company's cash balance decreased to $1.47 million as of December 31, 2023, from $3.79 million at the end of 2022.
• Coeptis acknowledges substantial doubt about its ability to continue as a going concern, citing the need for additional capital.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in terms of strategic partnerships and technology acquisition, the significant losses, declining cash balance, and going concern warning create a negative sentiment overall. The company's future is highly dependent on its ability to secure additional funding and successfully develop its product pipeline.

Positives

• The company secured an exclusive license for a stem cell expansion platform, enhancing its cell therapy capabilities.
• Coeptis made progress in its CD38-Diagnostic program, receiving FDA classification as a Class II device.
• The company successfully raised capital through private placements and sales.
• Operating expenses decreased significantly year-over-year.

Negatives

• The company experienced a significant net loss of $21.27 million in 2023.
• The company's cash balance decreased to $1.47 million.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has a history of losses and expects to incur further losses.

Risks

• The company may not be able to successfully implement its growth strategy.
• The company may have difficulties managing its anticipated growth.
• The company may not be able to achieve or maintain profitability.
• The company may not be able to initiate and complete preclinical studies and clinical trials.
• The company may not be able to obtain and maintain third-party relationships.
• The company needs to obtain financing to continue operations.
• The drug development and approval process is uncertain, time-consuming, and expensive.
• Competition in the biotechnology and pharmaceutical industries may result in lower revenues or profits.
• The company may not be able to maintain its listing on the Nasdaq Capital Market.

Future Outlook

The company expects to continue to generate operating losses and experience negative cash flow from operations at least through the end of 2023 or longer. The company believes that the ability to raise capital through equity transactions will increase liquidity and enable the execution of managements operating strategy.

Management Comments

• Management believes that additional financing as necessary will result in improved operations and cash flow.
• David Mehalick, Colleen Delaney, and Daniel Yerace agreed to waive their rights to a 2023 guaranteed bonus payment to maintain the ability to fund operations.

Industry Context

The company operates in the competitive biotechnology and pharmaceutical industries, facing competition from companies with greater resources and experience. The company is focused on developing innovative cell therapies for cancer and other diseases, which is a growing area of interest in the industry.

Comparison to Industry Standards

• The company's financial results are not directly comparable to established pharmaceutical companies with commercialized products, as Coeptis is primarily focused on research and development.
• The company's operating losses are typical for early-stage biotechnology companies that are investing heavily in research and development.
• The company's cash burn rate is a concern, and it will need to raise additional capital to continue operations.
• The company's strategic partnerships and licensing agreements are consistent with industry trends for early-stage biotech companies.

Management Changes

Related Party Transactions

• In September 2023, the Company entered into a transaction with AG Bio Life Capital I LP (AG), a Delaware limited partnership, where an employee of the Company is the general partner. The Company agreed to issue 600,000 shares of common stock of the Company (AG Shares) to AG, in exchange for $600,000, $100,000 payable in cash and the balance payable under a promissory note (AG Note).

Stakeholder Impact

• Shareholders face the risk of further dilution and potential loss of investment due to the company's need for additional capital.
• Employees may be affected by the company's financial instability and potential restructuring.
• Customers and partners may be impacted by the company's ability to deliver on its product development and commercialization plans.
• Creditors face the risk of non-payment due to the company's financial challenges.

Next Steps

• The company will continue to evaluate, prioritize, and optimize its pipeline portfolio.
• The company will focus on expanding its pipeline through strategic partnerships.
• The company will actively seek partnerships and strategic collaborations.
• The company will need to partner with firms for sales and marketing of future products.

Key Dates

Keywords

cell therapy, oncology, CD38, SNAP-CAR, GEAR-NK, biotechnology, clinical trials, licensing, stem cell, immunotherapy